Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2014

View Archived Issues

Korean patent details novel mutant haptoglobins

Screening of circulating patient-derived breast cancer cells for tailored treatment

uniQure acquires InoCard

Janssen describes different series of FLAP inhibitors for inflammatory diseases

Novel glucocorticoid receptor agonists show selectivity for transrepression over transactivation

G2B Pharma receives financing and right to in-license nasal delivery technologies

Galenica lays foundation for two independent companies

The Michael J. Fox Foundation for Parkinson's Research updates on its Partnering Program

Carfilzomib fails to meet primary endpoint in phase III multiple myeloma trial

U.S. DTRA supports preclinical development of Evolva's GC-072 for acute melioidosis

Novel nontreponemal EIA assay for the diagnosis of syphilis

Actelion Pharmaceuticals discloses new P2X7 antagonists

University of Toledo patents novel anticancer agents

Neuraceq launched in U.S.

New metalloenzyme inhibitors designed by Viamet Pharmaceuticals

Novartis disclose novel p53-Mdm2 interaction inhibitors

Skyepharma acquires rights to inhaled therapy platform from Pulmagen

Ligand Pharmaceuticals signs Captisol license agreement with Avion Pharmaceuticals

FDA grants fast track designation to SPN-810

FDA grants fast track designation to AG-221 for acute myelogenous leukemia

Miltenyi Biotec acquires Lentigen's lentiviral vector business

Ablynx awarded grant supporting nanobody development for ocular applications

BioCryst receives additional NIAID funding to advance development of BCX-4430

FDA accepts Pfizer's rLP-2086 BLA for review and grants priority review status

FDA approves Avastin in combination with chemotherapy for advanced cervical cancer

Questcor Pharmaceuticals acquired by Mallinckrodt

FDA approves Plegridy for relapsing multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...